title: Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
abstract: Elevated tumor necrosis factor (TNF)-alpha levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNF alpha plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.
authors.affiliation: Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Apostolia Maria
authors.initials: AM
authors.lastname: Tsimberidou
authors.forename: Tracey
authors.initials: T
authors.lastname: Waddelow
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Maher
authors.initials: M
authors.lastname: Albitar
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D016228:Endothelial Growth Factors / Q000097:blood; D000068800:Etanercept; D005260:Female; D017228:Hepatocyte Growth Factor / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008222:Lymphokines / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis*; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016879:Salvage Therapy; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D007074:Immunoglobulin G; D036341:Intercellular Signaling Peptides and Proteins; D015850:Interleukin-6; D008222:Lymphokines; D009363:Neoplasm Proteins; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D017228:Hepatocyte Growth Factor; D000068800:Etanercept